1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Parnax Lab Limited

Parnax Lab Limited

111.95
INR
+8.50
(+8.22%)
7.80EPS
17.54P/E
1.57BMarket Cap
Parnax Lab Limited
BSE:PARNAXLAB
(Bombay Stock Exchange)

Recent

price

111.95

P/E

ratio

17.54

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
- -
108.96
65.63
80.63
120.81
83.7
111.48
124.04
127.9
112.07
105.89
191.53
151.42
164.3
163.45
216.4
219.5
Revenue per Share
-0.18
-3.27
2.01
2.93
5.01
2.95
4.33
1.24
3.88
-3.43
-0.43
9.68
7.79
8.37
10.03
10.25
7.79
Basic EPS, GAAP
-0.17
1.23
6.5
-0.17
-0.3
4.1
6.13
9
-3.06
-5.22
2.08
-10.9
8.7
1.52
19.63
-23.91
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
10.96
21.21
21.64
24.57
29.56
32.5
36.88
38.23
42.01
38.56
38.26
49.1
54.11
62.32
72.35
82.83
- -
Book Value per Share
10.96
21.21
21.64
24.54
29.54
32.48
36.7
37.97
41.69
38.32
38.1
49
53.91
61.63
71.65
82.24
- -
Tangible Book Value per Share
3
9
9
9
9
9
9
9
9
9
9
9
11
11
11
11
11
Basic Weighted Avg Shares
- -
931
558
686
1,027
712
948
1,055
1,088
953
901
1,630
1,676
1,887
1,877
2,485
2,520
Sales/Revenue/Turnover
- -
-1.04
11.55
10.06
9.63
10.48
9.96
7.99
6.81
2.31
5.54
10.56
9.99
8.84
10.54
9.46
6.27
Operating Margin (%)
- -
19
19
21
30
29
38
37
38
45
52
59
65
70
74
80
83
Depreciation Expense
-1
-28
17
25
43
25
37
11
33
-29
-4
82
86
96
115
118
89
Net Income, GAAP
- -
- -
35.27
26.83
21.76
27.97
21.64
65.06
28.45
- -
- -
32.66
29.7
20.12
26.38
25.83
25.72
Effective Tax Rate (%)
- -
-3
3.06
3.64
4.14
3.52
3.89
1
3.03
-3.06
-0.4
5.06
5.14
5.09
6.14
4.74
3.55
Profit Margin (%)
36
-78
- -
50
69
-4
-56
-7
6
-68
-151
-62
-20
-64
-60
-28
- -
Working Capital
1
129
159
203
256
202
171
167
216
199
171
206
153
299
262
294
- -
LT Debt
35
181
184
209
252
277
314
326
358
329
326
483
623
717
832
953
- -
Total Equity
- -
- -
3.99
5.35
7.23
3.75
5.21
3.42
7.14
- -
- -
11.48
10.2
10.23
9.68
8.99
- -
Return on Invested Capital (%)
- -
- -
3.99
10.3
12.9
8.21
10.69
3.57
8
- -
- -
11.21
10.28
10.25
10.07
9.59
- -
Return on Capital (%)
-3.11
-25.96
9.38
12.69
18.5
9.5
12.49
3.3
9.67
-8.51
-1.11
20.42
15.62
14.37
14.89
13.21
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
534
- -
LT Borrowings
- -
217
- -
LT Finance Leases
- -
77
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
11
11
11
Market Capitalization
1,493
1,476
1,570

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
930
- -
Cash, Cash Equivalents & STI
- -
23
- -
Accounts Receivable, Net
- -
378
- -
Inventories
- -
362
- -
Total Current Liabilities
- -
958
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
534
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.08%
24.54%
14.49%
Free Cash Flow
-4.57%
12.3%
-221.75%
Net Income, GAAP
-241.38%
-465.29%
2.24%
Sales/Revenue/Turnover
15.8%
25.66%
32.39%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
501
484
402
490
1,877
2026
534
626
629
696
2,485
2027
568
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
3.47
2.97
1.06
2.55
10.03
2026
2.85
3.15
2.37
1.9
10.25
2027
0.37
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Parnax Lab Limited manufactures and exports pharmaceutical formulations, cosmetics, herbal and ayurvedic products, and nutraceuticals from its WHO-approved and EHS-compliant facilities in India, with operations extending internationally; the company, founded in 1982 and headquartered in Mumbai, forms part of the Naxpar Group and specializes in contract manufacturing of liquid orals, capsules, ointments, external powders, tablets, suspensions, and highly viscous products. Core offerings encompass oral formulations including cough expectorants such as NAXODEX Cough Syrup, Bronax Expectorant, and Pneumokof Expectorant; antacids like Gasknot Gel; anti-histamines such as Alerzine Syrup and Daslin NF Syrup; multi-vitamins and enzyme preparations; pediatric formulations like Febrinax Plus DS, Naxpar Gripe Water, and Brupaed Suspension; special geriatric formulations; cosmetics including Anti Druf Lotion; and nutraceuticals alongside other brands like Nax-P Syrup, Naxidex Syrup, Periact Syrup, Nerodex Cough Syrup, Kure Mouth Ulcer Gel, and Piromine Tablet. In recent developments, Parnax Lab maintains ongoing private label manufacturing for customers in India and abroad, sustains upgrades to its Silvassa facility for enhanced production capacity, and reports active share price momentum amid potential new product launches targeted for revenue growth in 2025.